PTO/SB/21 (07-06)

*		U.S. F		Approved for use through DW3312006. ONB 069 19057 rademark Office; U.S. DEPARTMENT OF COMMERCE commation unless it displays a valid OMB control number.
Under the Paper	work Reduction Act of 1995, no be	Application Number	10/580,9	940
∕ o Υ _R A	NSMITTAL	Filing Date	30 May 2	2006
/	FERM	First Named Inventor	John C.	LANG
OCT 0 5 20	06	Art Unit		
be used for all	er/	Examiner Name	1	
Total Number of P	ages in This Submission	Attorney Docket Number	2668 US	SF
		NCLOSURES (Check all	that apply	
Amendmer After After After Extension Express Al Cocument Certified C Document Reply to M Information Reply to M Incomplete	hittal Form Attached Att	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatic Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Cemarks	Address	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeals and Interferences (Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter (V) Other Enclosure(s) (please Identify below): 41 References and Return Card.
	SIGNATU	RE OF APPLICANT, ATT	ORNEY,	OR AGENT
Firm Name		. Alcon Res	earch, Ltd.	
Signature		Souranthu	J.	
Printed name		Teresa J	I. Schultz	
Date			Reg. No.	40,526
sufficient postage	at this correspondence is being	TIFICATE OF TRANSMIS g facsimile transmitted to the USI ope addressed to: Commissioner	PTO or den	AILING osited with the United States Postal Service with , P.O. Box 1450, Alexandria, VA 22313-1450 on
the date shown b Signature	P.C	InDara M	OK	enrål
		Data - Makanala		Date 25.September 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.4. This collection is estimated to 2 hours to complete, including no property of the process of the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting is completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the granular distribution of the USPTO. Time will vary depending upon the individual case. Any comments on the granular distribution of the USPTO. The will vary depending upon the individual case. Any comments on the granular distribution of the USPTO. T

Barbara McKenzie

Typed or printed name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 10/580,940

Filed: 30 May 2006

Examiner:

Group Art Unit: 1615



For: COMPOSITION AND METHODS FOR INHIBITING THE PROGRESSION MACULAR DEGENERATION AND PROMOTING HEALTHY VISION

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patent applications are not enclosed.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

*	By: Jrun Glaubl
Date	Teresa J. Schultz
	Registration No. 40,256
	(817) 551-4231

Address for Correspondence: Alcon Research, Ltd. Attn: Teresa J. Schultz 6201 S. Freeway, Mail Code TB4-8 Fort Worth, TX 76134-2099 Attorney Docket No.: 2668 US F

PTO/SB/08A (07-06)

Approved for use through 09/30/2008, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of Information unless it contains a valid OMB control number. Complete if Known

OCT 0 a 200a

Under the Paperwork Reduction Act of 1995 Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number 10/580,940 Filing Date 30 May 2006 First Named Inventor John C. LANG Art Unit Examiner Name

Attomey Docket Number 2668 US F

				DOCUMENTS	
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ^{2 (F Ansown)}	Publication Date MM-DD-YYYY	Name of Patentea or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/ZF/	1A	^{US-} 2002/182266 A1	12-05-2002	Bartels et al.	
1	1B	US- 2003/0064133	04-03-2003	Blatt et al.	
	1C	^{US-} 3,998,753	12-21-1976	Antoshkiw et al.	
	1D	^{US-} 4,254,100	03-03-1981	Keller et al.	
	1E	^{US-} 4,657,928	04-14-1987	Sorenson	
	1F	^{US-} 4,670,247	06-02-1987	Scialpi	
N/	1G	^{US-} 6,582,721	06-24-2003	Lang	
-	1H	^{US-} 6,649,195	11-18-2003	Gorsek	
		US-			
		US-	1		

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ "Number ⁴ " Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	™
/ZF/	1H	DE 101 09 798 A1	09-12-2002	Aventis Pharma		
/ZF/	11	WO 2005/065669 A1	07-21-2005	Alcon, Inc.		
			+			┝
					<u> </u>	一
						Г

/Zohreh Fay/ (12/05/2008) Considered Signature

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional), "See Kinac Codes of USPTO Patent Documents at https://www.pubp.cog/ or MPEP 0014 4. "Eiter Collect hat issued the document, by the two-letter code (WPO Sandard ST.3)," for Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Gind of document by the appropriate symbols as indicated on the document number WPO Sandard ST.10 if possible." "Applicant is to place a check mark fellighth language." Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USP/10 by process) an application. Confidentially of göverned by 3 b LSC. 122 mile PERF. 1.4. This descends a satinfiable to lister 2 miles from the complete to complete the form and complete the fo

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO INFORMATION DECLOSURE STATEMENT BY APPENDANT

(Use as many sheets as necessary)

of

5

2

Sheet

are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Application Number 10/580.940 Filing Date 30 May 2006 First Named Inventor John C. LANG Art Unit Examiner Name Attorney Docket Number 2668 US F

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ZF/ 2A AREDS Report No. 9, Age-Related Eye Disease Study Research Group: "A Randomized, Placebo-Controlle Clinical Trial of High-Dose Supplementation With Vitamins C And E And Beta Carotene For Age-Related Cataract And Vision Lose", Archives Of Ophthalmology, 119(10):1439-1452 (2001)			
	2B	BEEM, J BIOL CHEM 249:7298 (1974)	
	2C	BERMAN, BIOCHEMISTRY OF THE EYE, (Plenum Press, 1991), 309-330, 345-359 and 386-399	
	2D	BERNSTEIN et al., Retinal Tubulin Binds Macular Carotenoids, INV OPHTHAL & VIS SCI 38(1):167-175 (1997)	
	2E	BONE and LANDRUM, AM SOCIETY FOR NUTRITIONAL SCIENCES J NUTR, 133-992-998 (2003)	
	2F	CHANDLER et al., J. BIOL. CHEM 261:928-33 (1986)	
	2G	CHANEY, TEXTBOOK OF BIOCHEMISTRY WITH CLINICAL CORRELATIONS, John Wiley & Sons, 970-971 (1986)	
	2H	CHATTERJEE and GHOSH, ARCH, OPHTHALMOL 56:756-60 (1956)	
	21	FISCHER, J NUTRITION 113:462-469 (1983)	
\forall	2J	HAMMOND et al., Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns, VISION RESEARCH 36:2001-2012 (1998a)	

Signature	latted of reference considered, whether or not citation is in conformance with MPEF		itation if not in conformance and not
Character	/Zohreh Fay/ (12/05/2008)	Considered	

Date

considered. Include copy of this form with next communication to applicant.

considered, induced only this form with next communication to applicant.

14 Applicant's unique claim designation number (optional) 2. Applicant is not extra whom the property of the propert Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)

Approved for use through 09/30/2006, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		uction Ac	t of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitut	e for form 1449/PTO			Application Number	10/580,940		
INFO	DRMATION	DIS	CLOSURE	Filing Date	30 May 2006		
STATEMENT BY APPLICANT				First Named Inventor	John C. LANG		
	(Use as many she			Art Unit			
	(Use as many sne	ets as n	ecessary)	Examiner Name			
Sheet	3	of	5	Attorney Docket Number	2668 US F		

xaminer nitials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title on the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/ZF/	зА	HAMMOND et al., Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration, VISION RESEARCH 36:3003-3009 (1998b)		
	3В	HAMMOND et al., Dietary Modification of Human Macular Pigment Density, INV OPHTHAL & VIS SCI 38 (9):1795-1801 (1997)		
	3C	HANDELMAN et al., Biological Control of Primate Macular Pigment: Biochemical and Densitometric Studies, INV OPHTHAL & VIS SCI 32(2):257-267 (1991)		
	3D	HARRIS, NATURE 132:27-8 (1993)		
	3E	HOOPER et al., JAMA 244:1960-1961 (1980)		
	3F	JACQUES et al., Antioxidant Status in Persons With and Without Senile Cataract, ARCH. OPHTHALM. 108:337-340 (1988)		
	3G	KARCIOGLU, SURV OPHTHALMOL 27:114-122 (1982)		
	зн	LEURE-DUPREE, RETINA 2:294-302 (1982a)		
1	311	LEURE-DUPREE, INVEST OPHTHALMOL VIS SCI 23:425-34 (1982b)		
V	3J	MACHLIN et al., Free Radical Tissue Damage: Protective Role of Antioxidant Nutrients, FASEB J 1:441-445 (1987)		

L		billi for a side of whether a set election is in conformance with MDED	on Draw line through o	itation if not in conformance and not
١	Signature	720016111 dyr (1270072000)	Considered	
		Zohreh Fay/ (12/05/2008)		

Date

considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1. Applicants runged cataland designation number (goldona) 2. Applicant is to place a check mark next if English tenguage Translation is statehed.

This collection of information is required by 3° CFR 1.88. This information is expensive the public which is to fee found by the USPTO.

This collection is satirated to pix 2° CFR 1.88. This collection is satirated to pix 2° because the public which is to fee found by the USPTO.

This will very depending upon the implication of the completed application from to the USPTO. This will very depending upon the individual case, you comments on the amount of time you require to complete his form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, USP sent and Trademark Office, 9°, 0. Box 1456, Asharding, xy 2313-1450. D. NOTS SEND FEES OIL COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)

Approved for use through 09/30/2008, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

2668 US F

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/580.940 INFORMATION DISCLOSURE Filing Date 30 May 2006 STATEMENT BY APPLICANT First Named Inventor John C. LANG Art Unit (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number

Sheet

4

	T ou	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/ZF/ AANSOUR et al., Effect Of Antioxidant (Vitamin E) On The Progress Of Cataracts In Emory Mice, ARVC Abstract #47, pg 138 (1984 Supplement)			
- 4B		NEWSOME, D.A., Oral Zinc in Macular Degeneration, ARCH. OPHTHALMOL. 106:192-198 (1968)	
	4C	OHRLOFF and HOCKWIN, GRAEFE'S ARCH CLIN EXP OPHTHALMOL 222:79-81 (1984)	
	4D	ORTEN, HUMAN BIOCHEMISTRY 10th Edition, CV Mosby Co., p. 756-757 (1982)	
	PCT International Search Report of the related PCT Application No. PCT/US2004/041813, mailed June 1 2005		
	4F	PENNINGTON, J AM DIETETIC ASSOC 86:876-91 (1986)	
	4G	PURCELL et al., ARCH OPHTHALMOL 51:1-6 (1968)	
	4H	RINGVOLD, ACTA, OPHTHALMOLOGICA 63:227-2 80 (1985)	
	41	RUSSELL, ANN INT MED 99:227-239 (1983)	
V	4J	SEDDON et al., Dietary Carolenoids, Vitamins A, C and E, and Advanced Age-Related Macular Degeneration, JAMA 272(8):1413-1420 (1994)	

Signature /Zohreh Fay/ (12/05/2008) Date			Considered	
	Signature	/Zohreh Fay/ (12/05/2008)	Date	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Orbitations Include column is been written to the communication to approximate.

A popiciant's under column designation number (optional). 2 Applicant is under the first of the column and the column an Opcoding the repulsation. Commitmentally a government of State Control, Let all the 2 of Left 1.14. This community asserting the state of the completed application form to the USPTO. Time will knyr depending upon the individual case. Any comments on the properties of time you require to complete this form anotes suggestions for reducing this burden, should be sent to the Chief Information Officer, LISP 2 plants and Transferred Fig. 2.0 Sox 1450, Alexandris, VAZ 2215-1450. DO NOT SERVE FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)
Approved for use through 09/30/2006 OMB 0651-0031
rademark Office; U.S. DEPARTMENT OF COMMEDCE

	er the Paperwork Re	duction Ac	t of 1995, no persons a		of Information unless it contains a valid ON Complete if Known	
Substitute	:10110111111448/F10			Application Number	10/580,940	
			CLOSURE	Filing Date	30 May 2006	
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	John C. LANG	
	(Use as many sh	aate se ni	acareand	Art Unit		
	(osc as many sn	0013 83 III	cccaaary)	Examiner Name		
Sheet	5	of	5	Attorney Docket Number	2668 US F	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/ZF/	5A	SNODDERLY, Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins, AM J CLIN NUTR 62(suppl):14485-1461S (1995)		
	5B	SPARROW et al., 2001, Bioorganic & Medicinal Chemistry Letters, 11, 1533-1540		
	5C	SPECTOR et al., EXP, EYE RES. 33:673-681 (1981)		
	5D	SWANSON, BIOCHEM BIPHY RES COMM 45:1488-1496 (1971)		
	5E	VAN CAMPEN, J NUTRITION 97:104-108 (1970)		
	5F	VARMA et al., OPHTHALMIC RES 9:421-431 (1977)		
	5G	VARMA et al., OPHTHALMIC RES 26:141-148 (1994)		
	5H	WAGNER, GERIATRICS 40:111-125 (1985)		
V	51	WILLIAMS, PEDIAT RES 1:823-826 (1977)		
	5J			

TEVANINED. I	stial if reference applianced whather are not situation in in another second at APPER CO	O Describes the control of	 -
Signature	reality (resourced)	Considered	ı
Examiner	/Zohreh Fay/ (12/05/2008)	Date	ı

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. (22 and 37 CFR 1.18. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete ins form and/or suggestions for medulog this burden, should be sent to their Information Officer, U.S. Patient and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.